Switching from atorvastatin to another statin that is not metabolized by the CYP3A4 pathway can decrease platelet reactivity among patients after percutaneous coronary intervention (PCI) who respond ...

Please provide your email address to receive an email when new articles are posted on . Older adults taking a statin that is not metabolized by cytochrome P450 3A4 were at greater risk for adverse ...

Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding ...

Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...

The cytochromes P450 (CYPs) are the main enzyme family for metabolism of therapeutic drugs. CYP3A4 is the most active drug metabolizing CYP, and it plays a prominent role in adverse drug-drug ...

"The human cytochrome P450 family 3 subfamily A (CYP3A) serves an important role in the metabolic transformation of approximately 50% of marketed drugs, including fentanyl, midazolam, quetiapine, ...

Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration (FDA) approved drugs, reducing their effectiveness. However, how to prevent CYPs from ...

Efficacy and safety of obinutuzumab in the frontline treatment of CLL patients with comorbidities: The real-world results of Polish Adult Leukemia Group (PALG) retrospective analysis. This is an ASCO ...